BioRestorative Therapies VP buys shares worth over $10,000
- ByInvesting.com
- •
BioRestorative Therapies, Inc. is a clinical-stage company engaged in developing therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells (MSCs), collected from the patient's bone marrow. BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat)-derived stem cells (BADSC) to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.